Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of giant cell tumor of bone, inhibitor, applied in the field of oncology and diagnosis, can solve the problem of patient recurrence and so on
Active Publication Date: 2021-09-17
SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
View PDF6 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, both drugs have a range of side effects
11-13
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0207] Inhibition of CD44 reduces osteoclast formation in vitro
[0208] Firstly, the conditioned medium of SRGN-overexpressed hFOB1.19 cells and SRGN recombinant protein were used to induce the formation of osteoclasts in vitro.
[0209] The results showed that SRGN could significantly promote the formation of osteoclasts no matter using mouse primary bone marrow cells or RAW264.7 cell line. However, when a neutralizing antibody to CD44 was further added, the formation of osteoclasts was significantly inhibited ( figure 1 A-H).
[0210] In addition, the Cd44 gene was knocked out using CRISPR-Cas9 technology in RAW264.7 cells ( figure 1 I).
[0211] The results showed that after Cd44 was knocked out, neither the conditioned medium of SRGN overexpressed hFOB1.19 cells nor the SRGN recombinant protein could continue to promote the formation of osteoclasts ( figure 1 J-M).
[0212] These results demonstrate that inhibition of CD44 reduces osteoclast formation in vitro.
Embodiment 2
[0214] CD44 neutralizing antibody inhibits the formation of multinucleated giant cells and the growth of giant cell tumor of bone in mice
[0215]In this example, firstly, GCTB-19 giant cell tumor cells of bone were injected into immunodeficient NOD / SCID mice by way of tibial injection. One week after cell injection, mice were injected with CD44 neutralizing antibody or IgG control every two days. Since tumor cells are pre-labeled with luciferase, tumor cell growth can be tracked in vivo by injecting mice with a luciferase substrate for live imaging.
[0216] The results showed that in mice injected with CD44 neutralizing antibody, the growth of giant cell tumor of bone was significantly inhibited ( figure 2 A-C), and compared with the control group, the bone damage of these mice injected with CD44 neutralizing antibody was significantly alleviated, and the relative bone volume was also restored to a certain extent ( figure 2 A and D).
[0217] In addition, mouse leg bone...
Embodiment 3
[0219] Safety of CD44-targeted therapy
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a method for treating giant cell tumor of bone. Specifically, the invention provides application of a CD44 inhibitor, and the CD44 inhibitor is used for preparing the medicine for treating the giant cell tumor of the bone. Experimental results of the invention show that, the SRGN can be used as a novel biological marker for predicting the giant cell tumor of the bone and is used for diagnosing, typing and/or treating the giant cell tumor of the bone. Besides, in the tissue of giant cell tumor of the bone, the fusiform stromal cells can secrete glycoprotein of SRGN and can interact with the CD44 receptor on the mononuclear cells, so that the mononuclear cells are promoted to be differentiated into multinuclear giant cells. Therefore, the CD44 can be used as a target for clinically treating the giant cell tumor of the bone.
Description
technical field [0001] The invention relates to the fields of oncology and diagnosis, and in particular, the invention relates to a method for treating giant cell tumor of bone. Background technique [0002] Giant cell tumor of bone is a common primary bone tumor 1 , usually occurs in the metaphysis of the long bones of the extremities, including the distal femur, proximal femur, and proximal tibia 2 . Although giant cell tumor of bone is generally considered a benign tumor and rarely metastasizes, it is locally aggressive and often results in severe bone destruction 3,4 . [0003] Currently, the diagnosis and treatment methods for giant cell tumor of bone are very limited. The diagnosis of giant cell tumor of bone is mainly through histopathological and radiological evaluation, as well as the detection of H3.3G34W mutation. [0004] Currently, treatment options for giant cell tumor of bone are limited. In terms of clinical treatment, surgery is the most commonly used ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more